NCT05094804 2023-11-02
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
Phase 1/2 Unknown
Clinical Trials
8 trialsNCT01917279 2020-07-23
CAMELLIA
ChineseAMS
Phase 3 Unknown
NCT02007148 2019-02-27
MICADO
International Group of Endovascular Oncology
Phase 2 Unknown
NCT03147963 2017-05-10
Docetaxel 2-weeks Regimen in the Treatment of HER2 Negative Metastatic Breast Cancer
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT01630733 2016-07-01
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
Achieve Life Sciences
Phase 3 Unknown
NCT01126138 2011-05-04
Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)
ChineseAMS
Phase 3 Unknown
NCT00980603 2009-09-21
Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer
National Cancer Center, Korea
Phase 2 Unknown
NCT00448734 2009-01-21
A Study of Picoplatin and Docetaxel in Subjects With Prostate Cancer
Poniard Pharmaceuticals
Phase 1/2 Unknown